The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CABOSUN II: Results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC).
 
Andrew Johns
No Relationships to Disclose
 
Matthew T Campbell
Honoraria - AstraZeneca; Axdev; Curio Science; Exelixis; Medscape; Seagen; Targeted Oncology
Consulting or Advisory Role - EMD Serono; Exelixis; Pfizer; SeaGen
Research Funding - Apricity Health (Inst); Aravive (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - AVEO; SeaGen
Other Relationship - Curio Science
 
Pavlos Msaouel
Honoraria - Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Axiom Healthcare Strategies
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Eric Jonasch
Consulting or Advisory Role - aravive; Aveo; Calithera Biosciences; Eisai; Exelixis; Merck; NiKang Therapeutics; Novartis; Pfizer; Takeda
Research Funding - Arrowhead Pharmaceuticals (Inst); Merck; NiKang Therapeutics; Novartis
Travel, Accommodations, Expenses - Pfizer
 
Andrew Warren Hahn
No Relationships to Disclose
 
Jianjun Gao
Consulting or Advisory Role - AstraZeneca; AstraZeneca; crispr therapeutics; Infinity Pharmaceuticals; Janssen; Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca
 
Amishi Yogesh Shah
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Exelixis; Pfizer/EMD Serono
Research Funding - 4D Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst)
 
Sangeeta Goswami
No Relationships to Disclose
 
Amado J. Zurita
Honoraria - Janssen; Pfizer
Consulting or Advisory Role - AstraZeneca; Bayer
Research Funding - Infinity Pharmaceuticals
 
Lance C. Pagliaro
Research Funding - Exelixis (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
 
Mehmet Asim Bilen
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; SeaGen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Aradhana M. Venkatesan
Honoraria - Elsevier
Research Funding - Siemens Healthineers
 
Priya Rao
No Relationships to Disclose
 
Pheroze Tamboli
No Relationships to Disclose
 
Kanishka Sircar
No Relationships to Disclose
 
Rebecca Slack Tidwell
No Relationships to Disclose
 
Nizar M. Tannir
Stock and Other Ownership Interests - Amgen; Arcturus Therapeutics; Arcus Biosciences; BioCryst; Corvus Pharmaceuticals; First Trust Amex Biotech (FBT); Johnson & Johnson/Janssen; Merck; Nuvation Bio; Revolution Medicines; Surface Oncology; Vanguard Health Care; Xencor
Honoraria - AstraZeneca/Merck; Bristol-Myers Squibb; Eisai; Exelixis; Intellisphere; Merck Sharp & Dohme; Neoleukin Therapeutics; Oncorena
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Merck Sharp & Dohme; Nektar; Oncorena
Research Funding - Arrowhead Pharmaceuticals (Inst); Bristol Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Nektar (Inst); Novartis (Inst)